CTOS IS TEN YEARS OLDSARC IS TWO YEARS OLD

Happy Birthday, CTOS, SARC

Friend of SARCAllan Van Oosterom, M.D. Ph.D.

And they call us the killer B’s?

EORTC + SARC

SARCMission and Vision

• Collaborate to design clinical trials

• Further the knowledge regarding diagnosis and treatment of sarcoma

• Provide information to physicians, patients and families

• Utilize state of the art statistical design

Engage all appropriate and necessary resources to cure and prevent

sarcomas

StatisticiansD. BerryP. Thall

OperationsL. BakerD. Reinke

SARC CTOS

Institution – Multiple members of CTOSBoard of Directors – Majority from CTOS

SARC

StatisticiansD. BerryP. Thall

OperationsL. BakerD. Reinke

SARC CTOS

Institution – Multiple members of CTOSBoard of Directors – Majority from CTOS

Building Effective CollaborationsThrough SARC International

SarcomaResearchGroups

US GovtResearch

Mechanisms

SARC Executive Committee

• L. Baker

• B. Benjamin

• B. Maki

• G. Demetri

• L. Helman (consultant)

SARC Board of Directors

• Executive committee members• Charles Nearburg- Dallas• David Marsh- New York• Deborah Buks- Houston• Tim McCormick-Detroit• Piero Picci, MD-Rizzoli Institute• Frits van Coevorden, MD-Netherlands Ca Inst• Ad hoc

– Peter Thall (Stats)– Denise Reinke (Op office)

David Marsh

writer

radio personality

SARC board member

SARC Participants

– James Butrynski, MD • University of

Washington– Sant Chawla, MD

• Century City Hospital– Arthur Staddon, MD

• Pennsylvania Oncology– Martin Blackstein, MD

• Mt. Sinai, Toronto– John Murren, MD

• Yale University– Amir Shahlaee, MD

• University of Florida– William Tap MD

• UCLA*– Dennis Priebat, MD

• Washington Cancer Institute*

-Robert Benjamin, MDMDAnderson Cancer Center*

-Robert Maki, MD, PhDMSKCC*

-Scott Schuetze, MD, PhDUniversity of Michigan*

-Lee Helman, MDNCI-Pediatric Branch*

-Gina D’Amato, MDMoffitt Cancer Center

-Michael Fanucchi, MDEmory

-George Demetri, MDDana-Farber/Harvard *

-David Harmon, MDMGH/Harvard *

-Scott Okuno, MDMayo Clinic

Potential New Participants– Chris Ryan, MD

• Oregon Health Science

– Meg Von Mehren, MD• Fox Chase Cancer Center

– Kenneth Hande, MD• Vanderbilt Ingram Cancer Center

– INTERNATIONAL ALLIANCES– Piero Picci, MD

• Rizzoli Institute

– Ian Judson, MD• Royal Marsden Hospital

– Peter Hohenberger, MD• University of Heidelberg

SARC survey

• New patient annually– 4814

• Patients treated on protocol– 1790

• Patients treated on SARC protocols– 353

SARC survey

• 1790 accruals at SARC sites– 195 NCI (18 studies)– 353 SARC (3 studies)– 1242 pharma

• SARC partnering with pharma – Investigator initiated studies– sponsored trials

Protocols in Development

• Dasatinib– sarcoma

• Dasatinib– GIST

• AMG 706– Sarcoma– GIST

• Perfosine– chondrosarcoma and ASPS

What Makes SARC Special?

• Patients• Expertise• Commitment

• The same things that make most CTOS members and institutions special!

sarc

0

5

10

15

20

2001 2002 2003 2004 2005

year

institutions

protocols

THE SARC FUTURE

• Combined studies with EORTC

• SARC fall meeting part of CTOS

• FY2006 Energy Bill

• SARC DoD grant for MPNST

• SARC Website– NCCN guidelines– Sarcoma trials

SARC and Developmental SARC and Developmental TherapeuticsTherapeutics

• Sarcoma is recognized as an important model Sarcoma is recognized as an important model for drug discovery and developmentfor drug discovery and development

• Expanding the preclinical collaborations through Expanding the preclinical collaborations through SARCSARC– Peter Houghton is interested in STS modelingPeter Houghton is interested in STS modeling– Rich Gorlick is interested in bone sarcoma modelingRich Gorlick is interested in bone sarcoma modeling– Chand Khanna has developed a dog coop groupChand Khanna has developed a dog coop group

to evaluate treatment of dogs with sarcomasto evaluate treatment of dogs with sarcomas– SARC centers can provide access to broader range of SARC centers can provide access to broader range of

relevant tumor tissues through collaborationrelevant tumor tissues through collaboration

SARC and Developmental SARC and Developmental TherapeuticsTherapeutics

• Phase I investigators to test promising Phase I investigators to test promising new agents in relevant sarcomasnew agents in relevant sarcomas– Anthony Tolcher will collaborateAnthony Tolcher will collaborate

• Developmental Therapy Steering Developmental Therapy Steering Committee organizedCommittee organized– George Demetri-chairGeorge Demetri-chair

Chawla-Rosenfeld Development Therapeutic Symposia

Eugene and Maxine Rosenfeld Sant Chawla, MD